Centogene AG

www.centogene.com

CENTOGENE - transforming genetic data into medical decisions in the rare disease field.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

INOVIO ANNOUNCES STRATEGIC REORGANIZATION TO DELIVER DNA MEDICINES TO PATIENTS

INOVIO Pharmaceuticals, Inc. | February 01, 2023

news image

On January 31, 2023, INOVIO, a leading biotechnology firm focused on the development and commercialization of DNA medicines to protect and treat people from cancer, HPV-associated diseases, and infectious diseases, announced a strategic reorganization to meet operational efficiency commitments and better position the company to deliver DNA medicines to patients. Following the previously announced end of clinical development projects in late 2022, the restructuring is estimated t...

Read More

MedTech

ENTOS AND BIOMARIN ENTER INTO AGREEMENT FOR PRODUCT CANDIDATES INCORPORATING ENTOS' FUSOGENIX DRUG DELIVERY PLATFORM

Entos Pharmaceuticals, Inc., BioMarin | November 16, 2021

news image

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline. Under the agreement, Entos will create specially formulated product candidate...

Read More

Medical

BOTANICAL SOLUTION INC. (BSI) SECURES $6.1 MILLION IN SERIES A FIRST CLOSING

Botanical Solution Inc. | January 18, 2022

news image

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. Read More

Medical

CAPSIDA BIOTHERAPEUTICS ENTERS STRATEGIC COLLABORATION WITH KATE THERAPEUTICS TO MANUFACTURE KATETX'S NEXT-GENERATION GENE THERAPIES

PR Newswire | October 05, 2023

news image

Capsida Biotherapeutics Inc. and Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs. Under the terms of the agreement, Capsida will provide GMP manufacturing of KateTx's gene therapies ...

Read More
news image

MedTech, Industrial Impact

INOVIO ANNOUNCES STRATEGIC REORGANIZATION TO DELIVER DNA MEDICINES TO PATIENTS

INOVIO Pharmaceuticals, Inc. | February 01, 2023

On January 31, 2023, INOVIO, a leading biotechnology firm focused on the development and commercialization of DNA medicines to protect and treat people from cancer, HPV-associated diseases, and infectious diseases, announced a strategic reorganization to meet operational efficiency commitments and better position the company to deliver DNA medicines to patients. Following the previously announced end of clinical development projects in late 2022, the restructuring is estimated t...

Read More
news image

MedTech

ENTOS AND BIOMARIN ENTER INTO AGREEMENT FOR PRODUCT CANDIDATES INCORPORATING ENTOS' FUSOGENIX DRUG DELIVERY PLATFORM

Entos Pharmaceuticals, Inc., BioMarin | November 16, 2021

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline. Under the agreement, Entos will create specially formulated product candidate...

Read More
news image

Medical

BOTANICAL SOLUTION INC. (BSI) SECURES $6.1 MILLION IN SERIES A FIRST CLOSING

Botanical Solution Inc. | January 18, 2022

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. Read More

news image

Medical

CAPSIDA BIOTHERAPEUTICS ENTERS STRATEGIC COLLABORATION WITH KATE THERAPEUTICS TO MANUFACTURE KATETX'S NEXT-GENERATION GENE THERAPIES

PR Newswire | October 05, 2023

Capsida Biotherapeutics Inc. and Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs. Under the terms of the agreement, Capsida will provide GMP manufacturing of KateTx's gene therapies ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us